JAK3/BTK-IN-2
JAK3/BTK-IN-2 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004) [1]
Product Specifications
CAS Number
2674036-93-0
UNSPSC
12352005
Target
Btk; JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak3-btk-in-2.html
Solubility
10 mM in DMSO
Smiles
C=CC(N1C[C@H](NC2=C3C(NC=C3C4CC4)=NC(NC5=CN(C6CCOCC6)N=C5)=N2)CCC1)=O
Molecular Formula
C25H32N8O2
Molecular Weight
476.57
References & Citations
[1]Guobao Zhang, et al. Pyrimidopyrroles. Patent WO2021147952A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MOV10L1 (NM_001164106) Human Over-expression Lysate
Glycophorin A / CD235a (Erythrocyte Marker) (GYPA/1725R), CF594 conjugate, 0.1mg/mL
